Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis

Author： Sellmeyer D.   Black D.   Palermo L.   Greenspan S.   Ensrud K.   Bilezikian J.   Rosen C.  

Publisher： Springer Publishing Company

ISSN： 0937-941X

Source： Osteoporosis International, Vol.18, Iss.7, 2007-07, pp. : 973-979

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women

By Adami Silvano  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3259-3274

Informa Healthcare

Access to resources Recommend Favorite

Parathyroid hormone (1–84) and teriparatide in the treatment of postmenopausal osteoporosis

By Bogado1 César E   Massari2 Fabio E   Zanchetta3 José R  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 447-457

Future Medicine

Access to resources Recommend Favorite

Parathyroid hormone analogues in the therapy of osteoporosis

By Müller Markus   Pietschmann Peter  

Wiener klinische Wochenschrift, Vol. 120, Iss. 11-12, 2008-06 ,pp. : 321-324

Springer Publishing Company

Access to resources Recommend Favorite

Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment

By Chiang T.-I.   Chang I.-C.   Lee H.-S.   Lee H.   Huang C.-H.   Cheng Y.-W.  

Osteoporosis International, Vol. 22, Iss. 2, 2011-02 ,pp. : 577-585

Springer Publishing Company

Access to resources Recommend Favorite

The development of parathyroid hormone as anabolic therapy for osteoporosis: A timeline

By Dempster David   Reeve Jonathan  

Clinical Review in Bone and Mineral Metabolism, Vol. 4, Iss. 4, 2006-12 ,pp. : 227-231

Humana Press, Inc

Access to resources Recommend Favorite